Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122382 · ClinicalTrials.gov registry record · Phase 3
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,052
- Enrollment target
NCT00122382 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,052 participants.
The verdict
NCT00122382, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,052 participants
- Enrollment target
Study Summary
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Interventions
- DRUG placebo
- DRUG Abatacept
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,052 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122382
The ClinicalTrials.gov registry entry for NCT00122382 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,052 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00122382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00122382 about?
NCT00122382 is a clinical study titled "Remission and Joint Damage Progression in Early Rheumatoid Arthritis". This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
What is the current status of trial NCT00122382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,052 participants. The study started on 2005-07. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00122382?
The interventions under investigation include: placebo (DRUG), Abatacept (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00122382?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.